Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 8 (1999), Issue 3, Pages 147-151

Production of Secretory Leucocyte Protease Inhibitor (SLPI) in Human Pancreatic β-Cells

1Department of Surgery, Lund University, Lund, Malmö University Hospital, Malmö SE-205 02, Sweden
2Department of Surgical Pathophysiology, Malmö University Hospital, Malmö SE-205 02, Sweden

Copyright © 1999 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Secretory leucocyte protease inhibitor (SLPI) is a potent inhibitor of granulocyte elastase and cathepsin G, and also an inhibitor of pancreatic enzymes like trypsin, chymotrypsin and pancreatic elastase. SLPI has also been shown to inhibit HIV-1 infections by blocking viral DNA synthesis. Since SLPI is an inhibitor of pancreatic proteases we wished to investigate whether SLPI was also actually produced in the pancreas. M-RNA from human pancreatic tissue showed evidence of SLPI production using the reverse transcriptase polymer chain reaction technique (RTPCR). Using immunohistochemical methods SLPI was demonstrated in the β-ce1ls of the islets of Langerhans. The function could be local protease/antiprotease regulation or antiviral/antibacterial defence in the close vicinity of the cell surface, or even inside the β-cell itself.